List of articles in "Drug" category - Page 167

Zalospirone (WY-47846) is a selective 5-HT1A partial agonist of the azapirone chemical class. It was found to be effective in the treatment of anxiety and depression in clinical trials but […]

PWZ-029 is a benzodiazepine derivative drug with nootropic effects developed by WiSys It acts as a subtype-selective mixed agonist-inverse agonist at the benzodiazepine binding site on the GABAA receptor acting […]

SH-053-R-CH3-2′F is a drug used in scientific research which is a benzodiazepine derivative. It produces some of the same effects as other benzodiazepines but is much more subtype-selective than most […]

SB-408124 is a drug which is a non-peptide antagonist selective for the orexin receptor subtype OX1 with around 70x selectivity for OX1 over OX2 receptors and improved oral bioavailability compared […]

SB-334867 is an orexin antagonist. It was the first non-peptide antagonist developed that is selective for the orexin receptor subtype OX1 with around 50x selectivity for OX1 over OX2 receptors. […]

TCS-OX2-29 is an orexin antagonist. It was the first non-peptide antagonist developed that is selective for the orexin receptor subtype OX2 with an IC50 of 40nM and selectivity of around […]

GW-405833 (L-768242) is a drug that acts as a potent and selective partial agonist for the cannabinoid receptor subtype CB2 with an EC50 of 0.65nM and selectivity of around 1200x […]

Flephedrone also known as 4-fluoromethcathinone (4-FMC) is a stimulant drug of the cathinone chemical class.

LY-344545 is a research drug developed by the pharmaceutical company Eli Lilly which acts as an antagonist for the metabotropic glutamate receptor subtype mGluR5. It is an epimer of another […]

Eplivanserin (SR-46349; planned trade name Ciltyri) was an experimental drug for the treatment of insomnia which was being developed by Sanofi Aventis.Sanofi Aventis announced in December 2009 that it was […]